Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Psoriasis 7Lymphoma, Follicular 7Bronchiolitis Obliterans Syndrome 7Pruritus 5Arthritis, Rheumatoid 3Plaque, Amyloid 1Arthritis, Psoriatic 1

Interventions

Methotrexate 10Adalimumab 6tocilizumab 5Rituximab 5olokizumab 4tofacitinib 3Etanercept 3golimumab 2RC-18 2Abatacept 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1baricitinib 1andecaliximab 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Sulfasalazine 1Pharmaceutical Preparations 1Leflunomide 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1ISIS104838 1Hydroxychloroquine 1Folic Acid 1Double-Blind Method 1Chloroquine 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Arthritis, Rheumatoid × tofacitinib × Clear all
NCT04721821 2024-04-12

Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

Pfizer

Completed
7,807 enrolled 73 charts

Arthritis, Rheumatoid

NCT02092467 2021-08-17

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Pfizer

Phase 4 Completed
4,372 enrolled 22 charts

Arthritis, Rheumatoid

NCT00960440 2018-12-19

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Pfizer

Phase 3 Completed
399 enrolled 51 charts

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡